Lilly Just Dropped $2.3 Billion on a Drug Class Everyone Gave Up On

AJ1-11095 takes a fundamentally different approach. It's designed to bind JAK2 in its "Type II" (inactive) state, which Ajax believes can overcome the resistance mechanisms that hobble older drugs. If the existing JAK inhibitors are like trying to tackle a sprinter mid-stride, Ajax's drug aims to pin the runner down before they even stand up.

That distinction matters because it could mean AJ1-11095 works both as a first-line treatment and as a second option for patients whose disease has progressed on older therapies. Two bites at the apple from a single molecule.

Why JAK Inhibitors Became Radioactive

To understand why this deal is bold, you need to rewind to 2021. That's when results from the ORAL Surveillance trial of tofacitinib (Xeljanz), Pfizer's blockbuster JAK inhibitor for rheumatoid arthritis, sent shockwaves through the industry.

The trial enrolled RA patients aged 50 and older who had at least one cardiovascular risk factor, and it found that tofacitinib carried higher rates of major cardiovascular events, cancer, blood clots, and death compared to TNF blockers (the standard alternative). The FDA responded by expanding boxed warnings to the broader class of JAK inhibitors used in inflammatory diseases, including baricitinib and upadacitinib.

Suddenly, an entire drug class was wearing a scarlet letter. Doctors became more cautious about prescribing them, and the competitive landscape shifted toward biologics and other mechanisms.

But there's an important nuance that often gets lost in the headlines: the safety signal was strongest in older patients with pre-existing cardiovascular risk. Whether the same risks apply equally to younger, healthier populations (or to entirely different diseases like blood cancer) remains a more complicated question.

Lilly's Immunology Shopping Spree

The Ajax deal doesn't exist in a vacuum. Lilly has been on an acquisition tear across immunology and inflammation, steadily assembling a portfolio that looks less like a single bet and more like a diversified investment fund.

In 2024, Lilly closed its $3.2 billion acquisition of Morphic, scooping up an oral drug for inflammatory bowel disease. The company also picked up oral immunology assets from DICE Therapeutics. In 2026, reports indicate Lilly agreed to acquire Merida for $2.88 billion and signed a licensing deal with InnoCare Pharma worth up to roughly $3.35 billion.

Add those up, and Lilly has committed north of $10 billion in immunology and inflammation deals over just a couple of years. The pattern is clear: Lilly wants oral, mechanism-diverse therapies across IBD, dermatology, autoimmune disease, and now hematology.

Its existing approved portfolio already includes Omvoh (mirikizumab) for ulcerative colitis and Crohn's disease, Ebglyss (lebrikizumab) for atopic dermatitis, and the legacy psoriasis franchise Taltz (ixekizumab). Ajax fills a gap in the oncology-adjacent part of the JAK pathway, giving Lilly a foothold in myelofibrosis and polycythemia vera.

The Backstory on Ajax

Ajax was founded in 2019 by Ross Levine, Olli Silvennoinen, and Martin Vogelbaum, with deep roots in JAK biology research. Its drug discovery work was built in collaboration with Schrödinger, the computational chemistry company.

What makes the founding story interesting is that Eli Lilly was a founding strategic investor. So Lilly has been watching this asset from day one, seeing the preclinical data evolve and eventually deciding the science was ready for a full buyout. Other investors who joined along the way include EcoR1 Capital, Boxer Capital, Goldman Sachs Alternatives, RA Capital Management, Vivo Capital, and Point72, all of whom participated across Series B and C rounds.

For those investors, a $2.3 billion exit (even a milestone-loaded one) on a clinical-stage company is a strong return.

What This Means for the JAK Landscape

Lilly's willingness to write a multi-billion-dollar check for a JAK inhibitor sends a signal to the rest of the industry: the JAK story isn't over; it's evolving. The field is moving from broad, first-generation inhibitors toward precision approaches: more selective targeting, better dose control, smarter patient selection.

For competitors developing JAK-pathway drugs, this raises the stakes. Lilly's deep pockets and global clinical infrastructure could accelerate AJ1-11095's development timeline, bringing more trial activity and competitive pressure to the MPN space.

And for the broader immunology landscape, the deal reinforces a trend that's been building for years. Pharma companies aren't running away from mechanisms that have burned them before. They're betting they can engineer the problems away. Whether Lilly's wager on Type II JAK inhibition pays off depends entirely on what the clinical data shows.

The science is promising. The logic is sound. But in drug development, the only verdict that matters comes from the trials.

China Just Crashed the Obesity Drug Party

Hansoh Pharmaceutical just posted Phase 3 obesity data that rivals Eli Lilly's best-in-class numbers, and the weight loss curve wasn't even done climbing. The Novo-Lilly duopoly has a new problem, and it's coming from China.